The United States non-alcoholic steatohepatitis (NASH) biomarker market is anticipated to register a CAGR of 20.70% over the forecast period. The country’s market growth is facilitated by the surging prevalence of non-alcoholic fatty liver disease and the increasing numbers of obese patients. The base year considered for the market study is 2020, and the forecast years are from 2021 to 2026.

To learn more about this report, request a free sample copy

The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing annually, in the United States, and the trends also signify the condition’s increasing occurrence rate. Moreover, the disease is anticipated to become the most prevalent chronic liver condition across the country’s population. This is essentially accredited to the Type 2 diabetes and obesity epidemic in the United States. As a result, the likelihood of acquiring non-alcoholic steatohepatitis (NASH) is considerably increasing.

According to the 2018 estimations put forth by the NASH Education Program, the incidence of non-alcoholic steatohepatitis is projected to increase by 63%, from 2015 to 2030. The condition is also expected to become the leading cause of liver transplantation by 2020, across the United States. Currently, NASH is regarded as the second-most common indication of liver transplantation in the country, following chronic hepatitis C, as the condition’s prevalence continues to augment. Therefore, these factors play an important role in driving the market growth in the United States.

Gilead Sciences Inc, headquartered in the United States, is a biopharmaceutical company that develops, discovers, and commercializes therapeutics across areas of unmet medical needs within the United States, Europe, as well as internationally. It offers Yescarta, a chemical antigen receptor T-cell therapy, for adult patients with refractory or relapsed large B-cell lymphoma, and Letairis, an oral formulation of an endothelin receptor antagonist, for pulmonary hypertension, among others.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.